Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...

LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Non-Small Cell Lung Cancer.

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities might be on hot button ...